Gurugram, May 13, 2025 – Morepen Laboratories Ltd., a name synonymous with resilience in the Indian pharmaceutical landscape, has reached a historic financial milestone. The company posted its highest-ever Profit After Tax (PAT) of ₹118 crore for the financial year 2024-25 (FY25) and announced a dividend of ₹0.20 per share, marking its first dividend payout in 23 years. This decision highlights not just a profitable year, but a fundamental shift in the company’s growth trajectory and shareholder focus.

Strong Financial Performance in FY25

The financials tell a compelling story of operational strength and consistent growth.

• Gross revenue rose to ₹1,830 crore in FY25 from ₹1,704 crore in FY24 — a YoY increase of 7.4%.

• EBITDA surged by 11.5% to ₹192 crore, indicating solid margin management.

• The highlight was the PAT jump to ₹118 crore, establishing FY25 as Morepen's most profitable year to date.

• Earnings Per Share (EPS) increased 17% year-on-year to ₹2.20, reflecting strong shareholder value creation.

This upward trajectory reflects sustainable financial practices, improved efficiencies, and better cost management, positioning the company as a revitalized force in the pharmaceutical space.

Symbolic Dividend Marks Return to Shareholder Rewards

Sushil Suri, the Chairman and Managing Director of Morepen Laboratories Ltd., emphasized the significance of this move, stating:

“This moment is symbolic – it’s not just about distributing profits; it’s about rewarding trust. We always believe in the ‘Joy of Growing Together’. Declaring a dividend after 23 years reflects our financial strength, operational excellence, and long-term vision of sharing and caring.”

This ₹0.20 per share dividend is more than a number—it is a signal to the market and stakeholders that Morepen has moved past its turbulent years and now aims to actively reward its loyal investors.

API Segment Continues to Drive Growth

The Active Pharmaceutical Ingredients (API) business remains the backbone of Morepen’s operations, contributing ₹989 crore to the company’s top line.

• A significant 72% of API revenue came from exports, with the company having a presence in over 80 countries.

• APIs such as Loratadine, Atorvastatin, and Montelukast continue to be key drivers in both regulated and semi-regulated markets.

Export diversification and regulatory compliance in key geographies have allowed Morepen to expand its global reach and fortify its leadership position in the generic drug supply chain.

Medical Devices Business Grows 12% YoY

Another star performer was the Medical Devices Division, which recorded ₹496 crore in revenue, reflecting a 12% YoY growth.

• Demand for diagnostic devices like glucose monitors, blood pressure machines, and nebulizers has seen consistent upward movement post-COVID.

• Morepen continues to invest in innovative, user-friendly devices for the domestic and international markets.

This vertical not only provides revenue diversification but also aligns with India’s growing focus on preventive healthcare and at-home diagnostics.

Strengthening Global Footprint and Product Pipeline

Beyond the numbers, Morepen’s FY25 performance is also underpinned by forward-looking investments:

• Ongoing capacity expansions at API manufacturing facilities.

• R&D initiatives for new molecules and medical devices.

• Regulatory approvals from the USFDA, EU, and other global bodies, opening newer export opportunities.

These investments demonstrate Morepen’s intent to remain future-ready and innovation-driven.

Legacy, Challenges, and a New Chapter

Founded over four decades ago, Morepen has weathered economic shifts, regulatory challenges, and a highly competitive pharma environment. The 23-year gap in dividend declaration symbolizes the company’s focus on rebuilding its financial base before returning to shareholder distributions.

FY25 is not just about the numbers—it marks a turning point in the company’s narrative.

Outlook for FY26 and Beyond

Looking ahead, Morepen plans to:

• Further expand its export footprint, especially in emerging and regulated markets.

• Leverage the Make in India initiative to bolster domestic production.

• Launch new API molecules and diagnostic devices tailored to market needs.

• Strengthen its digital and e-commerce channels to boost product accessibility.

With its strong balance sheet, rising earnings, and renewed investor focus, Morepen is well-positioned to become a leading mid-cap pharma stock with a global edge.

Investor Confidence Reaffirmed

With the announcement of this landmark dividend, Morepen has not only rewarded its patient investors but also sent a clear message of confidence and stability to the market.

As the stock continues to attract institutional and retail interest, the FY25 performance sets the stage for even greater milestones in the years to come.

In Summary, Morepen Laboratories Ltd. has not just delivered a stellar year in numbers—it has rekindled investor optimism, proven its resilience, and laid a robust foundation for a new phase of inclusive growth and profitability.

The Upcoming IPOs in this week and coming weeks are Integrity Belrise Industries, Accretion Pharmaceuticals, Wagons Learning.

The Current active IPO are Integrity Infrabuild Developers, Virtual Galaxy Infotech.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.